XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborations and Other Arrangements - NMP (Details)
1 Months Ended 3 Months Ended 56 Months Ended
Aug. 31, 2013
USD ($)
item
Mar. 31, 2018
USD ($)
Mar. 31, 2018
USD ($)
Jan. 01, 2018
USD ($)
Dec. 31, 2017
USD ($)
NMP License and Commercialization Agreement          
Retained deficit   $ (317,217,775) $ (317,217,775)   $ (308,954,535)
Performance obligation period of recognition   6 years      
Deferred revenue   $ 363,266 363,266   $ 731,944
ASU 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]          
NMP License and Commercialization Agreement          
Retained deficit       $ 300,000  
Deferred revenue       $ (300,000)  
NMP | License And Commercialization Agreement          
NMP License and Commercialization Agreement          
Upfront payment received $ 1,000,000        
Performance obligation $ 1,000,000        
Performance obligation period of recognition   6 years      
Deferred revenue   $ 400,000 400,000    
Milestone revenue recognized     $ 0    
Period of time for termination notice to be given prior to the first commercial sale in Japan 90 days        
Period of time for termination notice to be given after the first commercial sale in Japan 6 months        
Period of time for termination notice to be given after Company receives regulatory approval in Japan but fails to launch the product 6 months        
NMP | Achievement Of Regulatory Milestones | License And Commercialization Agreement          
NMP License and Commercialization Agreement          
Number of cancer indications requiring achievement of regulatory goals | item 5        
NMP | Achievement Of Regulatory Milestones | Maximum | License And Commercialization Agreement          
NMP License and Commercialization Agreement          
Potential milestone payment $ 4,500,000